Research Solutions stock posts record fiscal profit

Published on 09/29/2026 at 11:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Research Solutions stock delivered USD 2.8 million in fiscal 2026 net income, up from USD 1.3 million. Revenue fell 1.53 percent to USD 48.3 million.

RSSS, US76132L1089, Illustration mit AI erstellt.

Research Solutions (ISIN US76132L1089) generated USD 2.8 million in fiscal 2026 net income, up from USD 1.3 million in fiscal 2025, according to PR Newswire on September 9, 2026. The result gives the Nasdaq-listed research workflow provider a stronger earnings profile even as sales declined.

Profit rises while revenue softens

Fiscal 2026 revenue was USD 48.3 million, down from USD 49.1 million in fiscal 2025, a decline of 1.53 percent. The company still lifted gross profit to USD 25.1 million from USD 24.2 million, while gross margin increased to 51.9 percent from 49.3 percent.

The shift came from the platform business. Platform subscription revenue reached USD 20.8 million, up 9.85 percent year over year, while transaction revenue fell to USD 27.5 million from USD 30.1 million. The mix change helped adjusted EBITDA rise to USD 5.8 million from USD 5.3 million.

Recurring revenue points to the mix shift

Annual recurring revenue reached USD 22.5 million at the end of fiscal 2026, up 7.8 percent from USD 20.9 million a year earlier. B2B ARR increased 14.1 percent to USD 16.2 million, while AI-related ARR reached USD 0.8 million.

Operating cash flow was USD 5.3 million in fiscal 2026, compared with USD 7.0 million in fiscal 2025, and cash stood at USD 12.6 million at June 30, 2026. The figures show a company balancing recurring-revenue expansion against weaker transaction volumes.

Market value and analyst view

Research Solutions had a market capitalization of USD 71.9 million as of September 28, 2026. Its 52-week range was USD 1.92 to USD 3.89, placing the market value within a broad trading band for the small-cap software company.

MarketBeat reported on September 20, 2026, that five research firms held a Moderate Buy consensus, with three Buy ratings and two Hold ratings. The average 12-month price target was USD 3.83.